The drug-based pipeline against restenosis.
More than 1 million percutaneous coronary interventions (PCIs) are performed yearly worldwide. Restenosis is the recurrent narrowing that can occur within 6 months following an initially successful PCI. Although drug-eluting stents have accomplished remarkable success, restenosis has not been eliminated and optimisation of both the polymers and drugs associated with them is desirable. This article reviews the presently available and potential preventive approaches against restenosis, including the sirolimus and paclitaxel drug-eluting stents.
Keller
Pierre-Frédéric
PF
Montreal Heart Institute, Department of Medicine, 5000 Belanger Street, Montreal, Canada.
Ibrahim
Reda
R
Tardif
Jean-Claude
JC
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000737:chemistry; D023903:Coronary Restenosis / Q000188:drug therapy* / Q000473:pathology*; D016503:Drug Delivery Systems / Q000379:methods*; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans
D000893:Anti-Inflammatory Agents; D015507:Drugs, Investigational